Adjuvant Gemcitabine Doubles Pancreatic Cancer Survival

(00:04:50) ASCO, 2008 May 31, Mary Ellen Schneider

Dr. Helmut Oettle is associated with the Charité School of Medicine, Campus Virchow-Klinikum, Berlin. 

Pancreatic cancer patients treated with adjuvant gemcitabine had double the 5-year OS rate compared with those who were only observed. 

See related videos to:
ASCO 2008, Clinical Trials

Related Links

View related Abstract No. LBA4504 »
News Story: Adjuvant Gemcitabine Chemotherapy Extends Survival Time in Patients With Resected Pancreatic Cancer »